Optimeos Life Sciences, Inc.

Optimeos Life Sciences, Inc. is a for-profit biotechnology company located in Princeton, New Jersey, focused on developing innovative nanoparticle-based delivery technologies for advanced therapeutic applications. The company specializes in creating cutting-edge platforms for gene therapy, targeted drug delivery, and therapeutic formulation using advanced nanoparticle technologies such as Coated Inverse Nanocarriers (CINCs). Registered in SAM.gov since 2010, Optimeos has positioned itself as a research-driven organization working at the intersection of nanotechnology, genetic medicine, and therapeutic innovation.

The company has secured multiple federal grants from prestigious agencies including the National Institute of Allergy and Infectious Diseases (NIAID), National Science Foundation, and National Center for Advancing Translational Sciences. These grants have supported research in diverse therapeutic areas such as in vivo stem cell gene therapy for primary immunodeficiencies, development of off-the-shelf CAR-Treg therapies for transplant rejection, mRNA-based treatments for urea cycle disorders, and long-acting depot formulations for therapeutic peptides and antibodies. Specifically, Optimeos has been awarded grants to develop innovative delivery mechanisms like inverse flash nanoprecipitation (IFNP), which enables high-loading and sustained release of complex biological therapeutics. Their research aims to address significant challenges in gene therapy and drug delivery, such as reducing treatment costs, expanding treatment availability, and improving patient outcomes through advanced nanoparticle platforms that can deliver genetic materials and therapeutic compounds more effectively and safely.